| A |
|
A 23-bp insertion in the EPCR gene and the risk of venous thrombosis
|
| Franco R. F., Maffei F. H. A., Piccinatto C. E., Zago M. A., Morelli V. M., Lourenço D. M., Ferreira A. C. P. |
| |
|
A 3' untranslated region (3' UTR) variation on the factor VII (FVII) gene changes completely the phenotype due to the Arg277Cys mutation in a patient with Type I FVII deficiency
|
| Peyvandi F., Garagiola I., Palla R., Marziliano N., Bader R., Bajetta M. T., Mannucci P. M. |
| |
|
A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy
|
| Smaradottir A., Bona R., Fritts L. |
| |
|
A case of an acquired inhibitor of Factor XIII
|
| Xiarchopoulou P., Andreopoulos A., Kotsi P., Kouramba A., Anastasopoulou J., Katsarou O., Tsoukala C., Karafoulidou A. |
| |
|
A case of catastrophic anti-phospholipid syndrome in pregnant woman with eclampsia
|
| Makatsaria A., Bitsadze V. O., Hizroeva D. H., Dolgushina N. V. |
| |
|
A case of compound type 2N/type 1 von Willebrand disease linked to a novel von Willebrand factor exon 18 mutation A2311G encoding for Met 771 val
|
| Friedman K. D., Gruppo R. A., Ebert D. D., Kakela J. K., Bellissimo D. B., Endres J. L., Wetzel N., Montgomery R. R. |
| |
|
A case of multiorgan atherosclerotic disease in patient affected by hyperhomocystinemia with multiple heterozygous mutations
|
| Cortellaro M., Gualdoni A., Arquati M., Porta B., Serino G., Rossi E. |
| |
|
A case of pregnancy and labor management in patient with recurrent thromboses and multigenic thrombophilia
|
| Makatsaria A., Bitsadze V. O., Dolgushina N. V. |
| |
|
A case series of 72 neonates with renal vein thrombosis: data from 1 to 800-No-Clots registry
|
| Kuhle S., Massicotte M. P., Chan A. K. C., Andrew M., Mitchell L. |
| |
|
A chimeric anti-human tissue factor antibody attenuates inflammatory responses in rhesus monkeys challenged with E. coli
|
| Zhu X. Y., Wang Q. Q., Hao P., Wong H. C., Jiao J. A. |
| |
|
A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: the @RISTOS project
|
| Agnelli G., Bolis G., Capussotti L., Scarpa R. M., Tonelli F., Bonizzoni E., Moia M., Rossi R., Sonaglia F., Valarani B., Bianchini C., Gussoni G. |
| |
|
A collaborative study to establish a Korea National Biological Standard for antithrombin III concentrate
|
| Kang H. N., Lee S. H., Kim S. N., Hong C. M., Lee K. H., Oh H. J., Yoo S. H., Shin I. S., Choi S. E., Lee S. H., Hong S. H. |
| |
|
A collaborative study to establish a Korean standard for factor VIII : C concentrate
|
| Kang H. N., Kim J. M., Kim S. N., Lee K. H., Yoo S. H., Shin I. S., Choi S. E., Lee S. H., Hong S. H. |
| |
|
A common mutation 4247T ® A (I1416N) causing type 2M von Willebrand disease in patients from three unrelated families previously diagnosed as severe type 1 VWD
|
| Lester W. A., Jones N. L., Guilliatt A. M., Surdhar G. K., Enayat M. S., Hill F. G. H. |
| |
|
A common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its association with a haplotype in the Korean population
|
| Park S., Yun T., Park S. R., Yoon S. S., Kim B. K., Kim S. O., Hong S. P., Chung H. J., Yoo W. D. |
| |
|
A comparative in vitro evaluation of seven von Willebrand factor concentrates
|
| Lethagen S., Carlson M., Hillarp A. |
| |
|
A comparative pharmacodynamic study of anti-Xa activity to evaluate the accumulation effect of Tinzaparin and Enoxaparin given at prophylactic dose over 8 days in elderly patients with impaired renal function
|
| Aghasaryan M., Mazoyer E., Mahé I., dit Bal Sollier C., Simoneau G., Berge N., Soulat T., Bergmann J. - F., Heilmann J.-J., Drouet L., Caulin C. |
| |
|
A comparative study of new generation blood sampling tubes for thrombophilia investigations
|
| Smith J. M., Bowyer A. E., Cooper P. C., Pastorelli D., Makris M., Kitchen S. |
| |
|
A comparison between routine plasma INRs and fingerstick whole blood INRs determinations, using three portable self-testing devices (Coagucheck®, Pro-Time®, Gem-PLC®) and a near-patient whole blood device (Thrombotrack®)
|
| De Monte P., Filippucci E., Boschetti E., Trottini S., Cavalieri G., Gresele P. |
| |
|
A comparison of argatroban and lepirudin outcomes
|
| Smythe M. |
| |
|
A comparison of assay methods for thrombin activatable fibrinolysis inhibitor (TAFI)
|
| Guimarães A. H. C., Van Tilburg N. H., Vos H., Bertina R.M., Rijken D.C., Guimarães A. H. C. |
| |
|
A comparison of spiral computed tomography and latex agglutination D-dimer assay in acute pulmonary embolism using pulmonary arteriography as Gold Standard
|
| Nilsson T., Soderberg M., Lundqvist G., Cederlund K., Larsen F., Rasmussen E., Svane B., Brohult J., Johnsson H. |
| |
|
A comparison of survival rates at 8–10 years for hip-fracture patients given thromboprophylaxis with enoxaparin vs. unfractionated heparin
|
| Borris L. C., Lassen M. R., Breindahl M., Jensen H. P. |
| |
|
A comparison of various evacuated blood collection tubes for monitoring warfarin therapy with Innovin
|
| Munro R., Hardingham S., Dorward N. R., Morris K. |
| |
|
A cytochrome P450 2C8/9-derived EDHF inhibits platelet adhesion to endothelial cells in vitro
|
| Krötz F., Riexinger T., Sohn H. Y., Bürkle M. A., Gloe T., Pohl U. |
| |
|
A dedicated system for standardized measurement of VASP phosphorylation in blood platelets and detection of thienopyridine resistance
|
| Poncelet P., Maunier T., Boulay-Moine D., Barragan P., Pons C., Nedelec J. |
| |
|
A deficiency of glycoprotein (GP) VI in platelets of a patient with gray platelet syndrome
|
| Nurden P., Kunicki T., Combrie R., Winckler J., Paponneau A., Pasquet J. M., Jandrot-Perrus M., Nurden A. |
| |
|
A different view on the inflammatory bowel disease – the role of adhesion molecules and angiogenic growth factors
|
| Araujo F., Magro F., Meireles E., Pereira P., Henriques I., Monteiro F., Dinis-Ribeiro M., Pereira C., Lacerda P., Tavarela Veloso F., Cunha-Ribeiro L. M. |
| |
|
A dose–response study of a recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement
|
| Kearon C., Comp C., Douketis D., Royds R., Yamada K., Gent M. |
| |
|
A dose-finding study of Tinzaparin in pediatric patients
|
| Kuhle S., Massicotte M. P., Dinyari M., Andrew M., Chan A. K. C., Mitchell D., Vegh P., Mitchell L. |
| |
|
A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter
|
| Verso M., Agnelli G., Bertoglio S., Di Somma C., Paoletti F., Ageno W., Bazzan M., Parise P., Quintavalla R., Naglieri E., Santoro A., Imberti D., Sorarù M. |
| |
|
A frequent, apparently silent, polymorphism in prekallikrein (Fletcher factor) gene
|
| Lombardi A., Cabrio L., Granzotto M., Sartori M. T., Girolami A. |
| |
|
A functional single-nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) associated with risk and outcome of meningococcal disease (MD)
|
| Kremer Hovinga J., Franco R. F., Zago M. A., Ten Cate H., Westendorp R. G., Reitsma P. H. |
| |
|
A genome-wide scan for genetic loci influencing levels of thrombin-activatable fibrinolysis inhibitor (TAFI)
|
| Almasy L., Cole S., Soria J. M., Souto J. C., Hixson J., Fontcuberta J., Blangero J. |
| |
|
A G-to-A mutation at -33 position in the promoter region of thrombomodulin gene and non-O blood group are associated with idiopathic venous thromboembolism: Taiwan Thrombophilia Study
|
| Lin J. S., Shen M. C., Yu Y. Y., Lin C. H., Hsueh S. Y., Fan H. C., Lin B. B., Hong M. H., Wang Y. C. |
| |
|
A human factor VIII inhibitor tolerating the endogenous FVIII with a unique A2 domain substitution in CRM + hemophilia A
|
| Habart D., Novotny M., Komrska V., Dobrovolna M., Vorlova Z. |
| |
|
A humanized monoclonal antibody against vWF A1 domain inhibits vWF:RiCof activity and platelet adhesion in human volunteers
|
| Machin S. J., Clarke C., Ikemura O., Kageyama S., Mackie I. J., Talbot J. A., Ikeda Y., Gyotoku Y. |
| |
|
A key role of the fast ATP-gated P2 X 1 cation channel in the thrombosis of small arteries in vivo
|
| Hechler B., Lenain N., Marchese P., Vial C., Heim V., Freund M., Cazenave J.-P., Cattaneo M., Ruggeri Z., Evans R., Gachet C. |
| |
|
A key role of the fast ATP-gated P2X1 cation channel in the thrombosis of small arteries in vivo
|
| Hechler B., Lenain N., Marchese P., Vial C., Heim V., Freund M., Cazenave J.-P., Cattaneo M., Ruggeri Z., Evans R., Gachet C. |
| |
|
A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) assembly
|
| Becker L., Webb B. A., Chitayat S., Nesheim M. E., Koschinsky M. L. |
| |
|
A meta-analysis on the benefit-to-risk ratio of Vitamin K antagonists (VKA) in the prevention of venous thromboembolism in major orthopedic surgery
|
| Mismetti P., Laporte S., Zufferey P., Epinat M., Decousus H. |
| |
|
A microsatellite polymorphism in the Heme Oxygenase – 1 gene promoter is associated with increased serum bilirubin and HDl levels but not with a decreased risk for coronary artery disease
|
| Endler G., Exner M., Schillinger M., Marculescu R., Sunder-Plassmann R., Raith M., Huber K., Mannhalter CH., Wagner O. |
| |
|
A microscopic evaluation of the influence of fluid dynamics on the clotting of a blood analog fluid
|
| Martin A., Christy J. R. E. |
| |
|
A modified ELISA procedure for platelet factor 4 with decreased heparin sensitivity
|
| Grimaux M., Caron N., Quignon V., Woodhams B. |
| |
|
A monoclonal antibody to the fibrinogen g chain alters clot structure and properties by producing thinner fibrin fibers arranged in bundles
|
| Scheiner T., Jirouskova M., Nagaswami C., Coller B. S., Weisel J. W. |
| |
|
A mouse model for inhibitor development in mild hemophilia A
|
| Van Helden P. M. W., Bril W. S., Zuurveld M. G., Hollestelle M. J., Fijnvandraat K., Reitsma P. H., Van Mourik J. A., Van Lier R. A. W., Mertens K., Voorberg J. |
| |
|
A multicenter study on the potency estimation of ReFacto
|
| Hubbard A., Sands D., Sandberg E., Seitz R., Barrowcliffe T. W. |
| |
|
A multicentre assessment of the endogenous thrombin potential using a continuous monitoring amidolytic technique
|
| Lawrie A. S., Gray E., Leeming D., Davidson S. J., Purdy G., Iampietro R., Craig S., Rigsby P., Mackie I. J. |
| |
|
A multinational observational cohort study in hospitalized medical patients of practices in prevention of venous thromboembolism and clinical outcomes: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)
|
| Anderson F. A., Decousus H., Bergmann J.F., Chong C., Froehlich J., Johnson J., Kakkar A., Merli G., Monreal M., Pavanello R., Pini M., Piovella F., Spyropoulos A., Turpie A.G.G., Tapson V., Zotz R. |
| |
|
A mutation leading to a stop codon in the FVIII gene is the cause of severe canine Hemophilia A
|
| Wilhelm C., Czwalinna A., Hoffmann M., Mischke R., Ganser A., Von Depka M. |
| |
|
A naturally homozygous deletion mutation of LYS9 or LYS10 in the A-chain of alpha-thrombin reduces the catalytic efficiency of the enzyme
|
| Akhavan S., De Cristofaro R., Peyvandi F., Mannucci P. M. |
| |
|
A new candidate mutation (C1272S) in type 2 A von Willebrand disease (VWD) affecting the disulfide loop responsible for the interaction of von Willebrand factor (VWF) with platelet glycoprotein Ib-IX
|
| Penas N., Perez A., Gonzalez-Boullosa R., Battle J. |
| |
|
A new computer algorithm for better dosage of oral anti-coagulants
|
| Kruithof C. J., Vanderschoot J. P. M., Meer Van Der F. J. M., Rosendaal F. R. |
| |
|
A new co-operative effect of low molecular weight polysaccharides and cell surface heparin sulfate in enhancing bFGF-induced endothelial cell differentiation
|
| Chabut D., Fischer A. M., Colliec-Jouault S., Laurendeau I., Matou S., Bros A., Helley D. |
| |
|
A new evidence of a relationship between store-operated calcium entry and the regulation of procoagulant phosphatidylserine exposure at the surface of stimulated cells
|
| Proulle V., Capiod T., Galitzine M., Martinez C., Freyssinet J. M., Le Deist F., Kerbiriou-Nabias D. |
| |
|
A new gene structure of disintegrin family: a subunit of dimeric disintegrin has short coding region
|
| Morita T., Okuda D., Koike H. |
| |
|
A new Global Plasma Fibrinolytic Assay for the rapid analysis of hyper-/hypo-Fibrinolysis: relationship with blood lipids and inflammatory markers
|
| Zouaoui Boudjeltia K., Amiral J., Vissac A.-M., Deschepper N., Saccomando E., Vanhaeverbeek M., Cauchie P. |
| |
|
A new global thrombosis test (GTT) shows impaired spontaneous thrombolytic activity in elderly and in habitual smokers
|
| Ikarugi H., Yamashita T., Aoki R., Ishii H., Kanki K., Yamamoto J. |
| |
|
A new method for identification of false-negative testing for lupus anticoagulant due to contamination of test plasma by platelet-derived micropatricles
|
| Gosavi S., Grosso L. E., Chance D., Kister J. L., Joist J. H. |
| |
|
A new platelet activation marker specific for activated integrin alpha2beta1: monoclonal antibody IAC-1
|
| Schoolmeester A., Vanhoorelbeke K., Lecut C., Heemskerk J. M. W., Hoylarts M. F., Deckmyn H. |
| |
|
A new preanalytical procedure using dried blood spot sample for total homocysteine determination
|
| Campolo J., Caruso R., Parolini M., Melotti D., Corbetta C., Bigi R., Parodi O., Accinni R. |
| |
|
A new protocol for inhibitor elimination in high responding hemophilia A patients
|
| Kreuz W., Linde R., Escuriola Ettingshausen C., Dunsch D., Köhl U., Figura S., Klingebiel T. |
| |
|
A new screening assay for abnormalities in the Protein C anticoagulant pathway
|
| Safa O., Smirnow M., Thomas E., Lawson D. |
| |
|
A new von Willebrand factor (VWF) online mutation and polymorphism database created on behalf of the ISTH VWF scientific and standardization committee (http://www.sheffield.ac.uk/vwf)
|
| Croft S. A., Maclachlan R., Lillicrap D. P., Goodeve A. C. |
| |
|
A new Von Willebrand ristocetin cofactor activity assay based on plasma glycocalicin
|
| Vanhoorelbeke K., Nijs A., Pareyn I., Peerlinck K., Hoylaerts M., Deckmyn H., Arnout J. |
| |
|
A new, noninvasive test for rapid detection of coagulation activation
|
| Borris L., Lassen M. R., Breindahl M. |
| |
|
A novel anti-oxidant, octyl caffeate, suppresses LPS/IFN-g-induced iNOS gene expression in rat aortic smooth muscle cells
|
| Hsiao G., Shen M. I., Sheu J. R. |
| |
|
A novel ELISA method for soluble fibrinogen and fibronectin complexes (FG–FN) in normal adult's and DIS patient's plasma
|
| Magari Y., Masuda Y., Shibata T., Okazaki T., Nagai T. |
| |
|
A novel endothelial receptor involved in red cell-endothelial cell adhesion
|
| Setty B., Stuart M. J. |
| |
|
A novel engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa
|
| Gale A. J., Pellequer J. L., Griffin J. H. |
| |
|
A novel method of measuring fibrinopeptide B for the detection of venous thromboembolism
|
| Morris T., Marsh J. J., Chiles P. G., Cal P. |
| |
|
A novel method to accurately measure collagen/serotonin-induced platelet aggregation by whole blood impedance aggregometry in humans
|
| Burggraaf J., Kemme M. J. B., Moerland M., Van Der Linden M., Cohen A. F. |
| |
|
A novel mutation (1668delC) in the glycoprotein IIb (CD41) gene causing Glanzmann's thrombasthenia
|
| Losonczy G., Kerényi A., Kiss C., Kappelmayer J., Balogh I., Muszbek L. |
| |
|
A novel pathway of phospholipase Cg2 activation downstream of the platelet integrin aIIbb3
|
| Wonerow P., Pearce A., Watson S. P., Vaux D. J. |
| |
|
A novel plasma proteinase that enhances incorporation of a2-antiplasmin into fibrin
|
| Lee K., Jackson K. W., Christiansen V. J., Chung K. H., Mckee P. A. |
| |
|
A novel platelet-specific delivery system for fibrinolytic agents
|
| Poncz M., Kufrin D., Eslin D. E., Bdeir K., Murciano J. C., Kuo A., Degen J. L., Sachais B., Cines D. B. |
| |
|
A novel point mutation in the transmembrane domain of the platelet glycoprotein IX associated with bernard–soulier syndrome
|
| Wang Z., Zhao X., Shi J., Han Y., Zhang W., Ruan C. |
| |
|
A novel R2464C candidate von Willebrand factor mutation in families with von Willebrand disease
|
| Al-Buhairan A. M., Nesbitt I. M., Coughlan T., Hampton K. K., Makris M., Peake I. R., Goodeve A. C. |
| |
|
A novel recombinant factor VIII produced by a human cell line functionally restores coagulation deficits in a mouse model of hemophilia A
|
| Han Y., Kauke T., Wang Y., Schröder C., Stüdemann C., Gluück B., Casademunt E., Lehnerer M., Hauser C. |
| |
|
A novel recombinant tissue factor assay for measuring the anti-Xa effect of Low-Molecular-Weight Heparin (LMWH): implications for interventional coronary procedures
|
| Laduca F., Lee T., El Rouby S., Zucker M., Cohen M. |
| |
|
A novel role for cytosolic calcium in down-regulating integrin aIIbb3 activation and platelet adhesiveness
|
| Kulkarni S., Jackson S. P. |
| |
|
A novel r-polypeptide, kunitz-type inhibitor with high specificity for plasma kallikrein and potential for therapeutic use
|
| Mackie I., Purdy G., Lawrie A. S., Williams A., Machin S. J. |
| |
|
A novel type 1 von Willebrand disease causing mutation (S49R) in the von Willebrand factor pro-peptide that affects von Willebrand factor multimerization and secretion
|
| Messenger S. L., Abuzenadah A. M., Gursel T., Ingerslev J., Peake I. R., Daly M. E., Goodeve A. C. |
| |
|
A patient with factor V Leiden who rapidly developed fatal heparin induced thrombocytopenia
|
| Davidson S. J., Burman J. F., Chaubey S., Desouza A. |
| |
|
A pharmacokinetic study of tinzaparin in pediatric patients
|
| Kuhle S., Massicotte M. P., Dinyari M., Marzinotto V., Mitchell D., Pieniaszek H., Andrew M., Chan A. K. C., Vegh P., Mitchell L. |
| |
|
A phase I/II trial of AAV-mediated, liver-directed gene transfer for hemophilia B
|
| Manno C. S., Glader B., Hutchison S., Dake M., Razavi M., Herzog R. W., Mcclelland A., Rustagi P., Johnson F., Rasko J. E. J., Hoots K., Blatt P., Leonard D. G. B., Addya K., Konkle B., Chew A., Couto L. B., Arruda V. R., Kaye R., Ozelo M. C., Pierce G., High K. A., Kay M. A. |
| |
|
A phosphatidylserine binding site distinct from the C2 domain membrane attachment site regulates the assembly and activity of the human prothrombinase
|
| Majumder R., Quinn-Allen M. A., Kane W. H., Lentz B. R. |
| |
|
A polyphenol mixture inhibits collagen induced platelet aggregation
|
| Celestini A., Pignatelli P., Violi F., Pulcinelli F. M. |
| |
|
A postoperative platelet count threshold contributes to an earlier diagnosis of heparin-induced thrombocytopenia and improved platelet recovery in cardiac surgery patients. The HITME (Heparin-Induced Thrombocytopenia Multicenter Evaluation) study
|
| Prechel M. M., Gerdisch M., Wallis D. E., Birger-Botkin S., Jeske W. P., Jacobs K., Castellanos Y., Messmore H. L., Bakhos M., Walenga J. M. |
| |
|
A program for the point of care testing (POCT) of the ACT to ensure safe control of heparinization in coronary angioplasty
|
| Creagh M. D., Carson P. J., Johnstone T., Loar P. |
| |
|
A promising therapeutic strategy in acute promyelocytic leukemia (APL): disruption of MEK/ERK, arsenic and retinoids
|
| Lopez-Pedrera C., Barbarroja N., Buendía P., Torres A., Dorado G., Velasco F. |
| |
|
A proposed ISTH revised classification for the anti-phospholipid syndrome
|
| Nash M., Camilleri R. S., Kunka S., Mackie I. J., Machin S. J., Cohen H. |
| |
|
A proposed mechanism for reduced bleeding of direct thrombin inhibitors as compared to heparin as measured by thromboelastography
|
| Young G., Yonekawa K. E., Nagakawa P. A., Shedarowich K., Nugent D. J. |
| |
|
A prospective analysis of hemostasis in systemic inflammatory response syndrome (SIRS) with acute renal failure
|
| Malyszko J., Czaban S., Malyszko J. S., Krajewski J., Siemiatkowski A., Mysliwiec M. |
| |
|
A prospective implementation study of out-patient treatment with subcutaneous low-molecular-weight heparin and oral anti-coagulants in patients with deep venous thrombosis in routine clinical practice
|
| Zidane M., Van Hulsteijn L. H., Brenninkmeijer B. J., Huisman M. V. |
| |
|
A prospective multicentre study assessing the random error rates of routine coagulation tests
|
| Malan E. |
| |
|
A prospective randomized study to assess the usefulness of venous compression ultrasonography (CUS) and plasma d-dimer (DD) assay in the decision to discontinue treatment with a vitamin K antagonist (VKA) after an acute deep-vein thrombosis (DVT)
|
| Drouet L., Bosson J. L., Lanoye P., Dutrey-Dupagne C., Gence D. |
| |
|
A prospective randomized trial of anti-platelet therapies in patients with carotid artery disease (preliminary results)
|
| Lewis D. R., Chen W., Morel-Kopp M.-C., Appleberg M., Fisher C. M., Ward C. M. |
| |
|
A prospective study examining the effect of a two milligram dose of oral Konakion given to patients with an INR > 8
|
| Wright D., Seal J. |
| |
|
A proteomic approach to identify plasma lipoprotein-associated proteins with a potential role in atherothrombosis
|
| Rezaee F., Casetta B., Levels H., Speijer D., Meijers J. C. M. |
| |
|
A quantitative trait locus on chromosome 11 is the major genetic determinant of homocysteine plasma levels. Results from the GAIT Project
|
| Souto J., Blanco-Vaca F., Soria J. M., Buil A., Ordoñez-Llanos J., Lathrop M., Almasy L., Stone W., Blangero J., Fontcuberta J. |
| |
|
A randomized clinical trial of oral anticoagulant therapy in patients with the antiphospholipid syndrome: the WAPS study
|
| Finazzi G., Marchioli R., Barbui T. |
| |
|
A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer
|
| Anderson D., Goodyear M., Burnell M., Dolan S., Wasi P., Barnes D., Macleod D., Burton E., Andreou P., Couban S. |
| |
|
A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus study
|
| Agnelli G., Bergqvist D., Cohen A., Gallus A., Gent M. |
| |
|
A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely Ill medical patients: the PREVENT medical thromboprophylaxis study
|
| Leizorovicz A., Cohen A. T., Turpie A. G. G., Olsson C. G., Vaitkus P. T., Goldhaber S. Z. |
| |
|
A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by Warfarin Sodium
|
| Hull R. D., Pineo G. F., Mah A. F., Brant R. F. for the LITE Investigators |
| |
|
A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer
|
| Hull R., Pineo G. F., Mah A. F., Brant R. F., For The LITE Investigators† |
| |
|
A randomized, double-blind, placebo-controlled study of the safety and pharmacokinetics of a single dose of recombinant Factor XIII in healthy volunteers
|
| Reynolds T.C., Butine M.D., Gunewardena K.A., MacMahon M., Zuckerman L.A., Bishop P.D., Morton K.M. |
| |
|
A rapid chromogenic method for determination of TAFI in plasma samples
|
| Stürzebecher J., Prasa D., Ziegler H., Wilmer M., Wikström P. |
| |
|
A recombinant von Willebrand factor fragment inhibits binding of von Willebrand factor to glycoprotein Ib-IX
|
| Zhu H., Wang Y., Bai X., Ruan C. |
| |
|
A relationship between SHBG and APCr during OC treatment
|
| Van Rooijen M., Silveira A., Hamsten A., Bremme K. |
| |
|
A retrospective evaluation of the use of B-domain deleted recombinant Factor VIII (ReFacto®) administered by continuous infusion during surgical procedures
|
| Schulman S., Roussel-Robert V., Stieltjes N., Negrier C., Reynaud J., Villar A., Pouzol P., Savidge G. F., Altisent C., Auerswald G. |
| |
|
A risk assessment model for identifying medical patients who should receive thromboprophylaxis
|
| Cohen A., Alikhan R., Arcelus J., Bergmann J. - F., Haas S., Merli G., Spyropoulos A., Tapson V., Turpie A. G. G. |
| |
|
A role for the thiol isomerase activity of a IIbb 3 in receptor clustering
|
| Robinson A., O'Neill S., Moran N. |
| |
|
A role for the thiol isomerase protein P5 in platelet function
|
| Jordan P. A., Graham G. J., Hubbard G. P., Sage T., Stevens J. M., Gibbins J. M. |
| |
|
A sensitive method for tissue factor mRNA quantitation
|
| Anders M., Tenno T., Åberg M., Siegbahn A. |
| |
|
A sensitized ENU mutagenesis screen for dominant genetic modifiers of thrombosis in the factor V Leiden mouse
|
| Westrick R. J., Manning S. L., Siemieniak D. R., Aiyagari A., Ginsburg D. |
| |
|
A simplified assay for VWF cleaving protease (ADAMTS-13) activity and inhibitor in plasma
|
| Knovich M. A., Craver K. T., Matulis M. D., Owen J. |
| |
|
A single dose (0.8 g kg) of intravenous immunoglobulin in children with acute immune thrombocytopenic purpura
|
| Unuvar A., Devecioglu O., Anak S., Saribeyoglu E., Citak A., Karakas Z., Agaoglu L. |
| |
|
A single point mutation of asparagine 511 to serine is responsible for the increased rate of cleavage of high molecular weight in Lewis rat, which is genetically susceptible to inflammatory stimuli
|
| Pixley R., Isordia-Salas I., Parekh H., Li F., Sartor R. B., Colman R. W. |
| |
|
A single-center prospective study of clinical and genetic thrombophilic risk factors for deep venous thrombosis (DVT) in 510 patients undergoing elective lower limb surgery
|
| Joseph J., Courtenay B., Neil M., Mcgrath M., Ma D. D. F. |
| |
|
A snake venom metalloproteinase reduces neutrophil-platelet adhesion through down-regulation of PSGL-1 expression
|
| Tseng Y. L., Lee C. J., Huang T. F. |
| |
|
A sporadic case of gray platelet syndrome
|
| Barreira R., Moura Nunes J. F., Parreira A., Crespo F. |
| |
|
A study of 10 rapid d-dimer tests for the exclusion of acute venous thromboembolism
|
| Gardiner C., Mackie I. J., PENNANEAC'H C., Abe G., Walford C., Machin S. J. |
| |
|
A study of 130 Italian patients on anti-coagulant treatment: how variant alleles of gene CYP2C9 influence requirement dose of warfarin during the induction period of treatment
|
| Peyvandi F., Spreafico M., Siboni S., Moia M., Mannucci P. M. |
| |
|
A study of gene expression profiles during megakaryocytopoiesis
|
| Jacquelin B., Kortulewski T., Pawlik A., Vaigot P., Gidrol X., Tronik-Le Roux D. |
| |
|
A study of the protection of plasmin from antiplasmin within an intact fibrin clot during the course of clot lysis
|
| Schneider M., Nesheim M. |
| |
|
A study on the changes in of plasma coagulative, anti-coagulative, fibrinolytic activities in patients with cerebral infarction and the therapy with low molecular weight heparin
|
| Wensheng L., Jichuan S. |
| |
|
A survey of streptokinase products shows inconsistencies in the quality of thrombolytic products used worldwide
|
| Longstaff C., Whitton C. M. |
| |
|
A systematic analysis of the effects of a thrombin-specific inhibitor, argatroban in HIT
|
| Kelton J., Moore J. C., Santos A. V., Warkentin T. E. |
| |
|
A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function
|
| Hoffman M., Meng Z. H., Wolberg A. S., Monroe D. M. |
| |
|
A systematic review of the accuracy of ultrasound in the diagnosis of asymptomatic deep venous thrombosis: preliminary results
|
| Kassai B., Leizorovicz A., Cucherat M., Sonie S., Boissel J., - P., Gueyffier F., Shah N. R., Greenland S. |
| |
|
A systematic review of venous thromboembolism and long distance travel: strength of association and evidence for prevention
|
| O'Donnell M., Kearon C., Julian J., Hirsh J. |
| |
|
A thrombomodulin (TM) gene promoter variant (TM-33G > A) in type 2 diabetes
|
| Ireland H., Konstantoulas C., Braitch M., Goodall A. H., Toh C. H., Mather H., Humphries S. E. |
| |
|
A transcobalamin gene polymorphism and the risk of deep venous thrombosis
|
| Ferreira A. C. P., Lourenço D. M., Morelli V. M., Piccinatto C. E., Vannucchi H., Zago M. A., Maffei F. H. A., Franco R. F. |
| |
|
A transgenic mouse model demonstrates the efficacy of Factor VIII ectopically expressed in platelets for Haemophilia A treatment
|
| Yarova H., Kufrin D., Eslin D. E., Zhu H., Camire R., Wilcox D., Montgomery R. R., Kowalska M. A., Poncz M. |
| |
|
A transient factor V inhibitor associated with vasculitis
|
| Macartney C., Sharkey R., Cooke P., Murray P., Anderson J. A. M. |
| |
|
A two-stage thrombophilia screening protocol: more efficient use of laboratory tests
|
| Leyte A., Van Zanten A. P., Van Der Heide Y. T., Smits P. H. M., ten cate H., Brandjes D. P. M. |
| |
|
A type 2A (Group II) von Willebrand disease mutation (Leu1503Glu) associated with a minimal loss of high molecular weight von Willebrand factor (VWF) multimers
|
| Hough C., Lillicrap D., O'Brien L., Sutherland J., Benford K., Racz H., Rapson D. |
| |
|
Abciximab reduces monocyte tissue factor after carotid angioplasty and stenting: role of monocyte platelet cross talk in cerebral microembolization
|
| Kopp C. W., Steiner S., Nasl C., Seidinger D., Mlekusch I., Lang W., Bartok A., Bernhofer P., Ahmadi R., Minar E., Kopp C. W., Steiner S., Nasl C., Seidinger D., Mlekusch I., Lang W., Bartok A., Bernhofer P., Ahmadi R., Minar E. |
| |
|
Abciximab therapy post elective coronary artery stenting does not prevent a troponin rise mediated by increased levels of platelet P-selectin and platelet-monocyte aggregates
|
| Connor D. E., Joseph J. E., Baron D. W., Muller D. W., Roy P., Wilson S. W., Ma D. D. F. |
| |
|
Ability of d-dimer to reduce the need for diagnostic imaging in patients with suspected pulmonary embolism: A randomized trial
|
| Kearon C., Ginsberg J. S., Julian J., Douketis J., Turpie A. G. G., Bates S., Lee A., Crowther M., Weitz J., Brill-Edwards P., Linkins L., Wells P., Anderson D., Kovacs M., Bonilla-Escobedo L., Mccarty D., Hirsh J., Gent M. |
| |
|
Abnormal subcellular localization of neutrophil nonmuscle myosin heavy chain-A (NMMHCA) is associated with MYH9 mutations in patients with autosomal dominant macrothrombocytopenia with leukocyte inclusions
|
| Matsushita T., Kunishima S., Kojima T., Kamiya T., Hirano M., Saito H. |
| |
|
Abnormal thrombogenesis and endothelial damage/dysfunction is related to ‘nondipping’ pattern of nocturnal blood pressure in patients with coronary artery disease
|
| Lee K. W., Lip G. Y. H. |
| |
|
Abnormal thrombogenesis and endothelial damage/dysfunction is related to high pulse pressure in patients with coronary artery disease
|
| Lee K. W., Lip G. Y. H. |
| |
|
Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study
|
| Lassen M., Bauer K. A., Eriksson B. I., Turpie A. G. G. |
| |
|
Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia. Preliminary results of a family cohort study
|
| Libourel E. J., Bank I., Middledorp S., Hamulyak K., Koopman M. M. W., Van Pampus E. C. M., Prins M. H., Buller H. R., Van Der Meer J. |
| |
|
Absolute risk of venous thromboembolism (VTE) associated with a single or combined thrombophilic disorder. Preliminary results of a family cohort study
|
| Libourel E., Bank I., Middeldorp S., Hamulyak K., Koopman M. M. W., Van Pampus E. C. M., Prins M. H., Buller H. R., Van Der Meer J. |
| |
|
Accuracy of laboratory diagnosis of familial thrombophilia, 2001–2002: UK NEQAS experience
|
| Preston F. E., Jennings I., Kitchen S., Woods T. A. L. |
| |
|
Acquired hemophilia: a multicentric study. Spanish group on acquired hemophilia
|
| Marco P. |
| |
|
Acquired platelet dysfunction with eosinophilia in children: A tropical disease present in Venezuela
|
| Ruiz-Sáez A., Nuñez L., Feijoo R., Certad G., Arenas A., Rodriguez L., Ferrara R., Jimenez R., Bosch N. |
| |
|
Acquired postpartum hemophilia: report of a case
|
| Stankovic S., Stojanovic A. S., Siljanovski N. S., Smilevska T. S., Pavkovic M. P., Hadzi-Pecova L. H. |
| |
|
Acquired protein S deficiency in HIV-infected patients is corrected under HAART
|
| Toulon P., Bachmeyer C., Metge S. |
| |
|
Acquired prothrombotic-associated factors in cerebral venous thrombosis (CVT)
|
| D'Amico E., Camargo E. C. S., Villaça P. R., Massaro A. R., Bassitt R. P., Bacheschi L. A., Scaff M., Chamone D. A. F. |
| |
|
Acquired von Willebrand Syndrome: four cases associated with monoclonal gammopathy
|
| Slaoui M., Borel Derlon A., Gautier P., Letellier P., Le Querrec A. |
| |
|
Acquired von Willebrand's disease not responding to Rituximab
|
| Moll S., Fuller III E., Cassara J., Rick M. E. |
| |
|
Activated clotting time guided dosage optimization of a low molecular weight heparin (tinzaparin) for surgical and interventional indications
|
| Fareed D., Iqbal O., Tobu M., Mousa S., Hoppensteadt D., Ma Q., Lietz H., Messmore H. L., Coyne E. |
| |
|
Activated factor V is inactivated by activated protein C in the absence of APC cleavage sites at Arg306, Arg506 and Arg679
|
| Van Der Neut Kolfschoten M., Dirven R., Tans G., Rosing J., Vos H. L., Bertina R. M. |
| |
|
Activated factor VII enhances whole blood fibrinolysis due to urokinase-type plasminogen activator
|
| Takahashi Y., Kawaguchi C., Hanesaka Y., Izaki K., Yoshioka A. |
| |
|
Activated platelets and platelet-derived microvesicles (PMV) transfer tissue factor (TF) to monocytes but not to neutrophils
|
| Lösche W., Scholz T., Temmler U., Zhao L., Spangenberg P., Heptinstall S. |
| |
|
Activated platelets induce migration, proliferation and gene expression in human vascular endothelial cells
|
| Eigenthaler M., Schwarz U. R., Schinke B., Kobsar A. |
| |
|
Activated protein C (APC) blocks p53-mediated apoptosis in ischemic human brain endothelium through endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR-1)
|
| Griffin J. J., Cheng T., Liu D., Fernandez J. A., Fukudome K., Zlokovic B. V. |
| |
|
Activated protein C anticoagulant activity mediated by phospholipid vesicles is enhanced by cholesterol and sphingomyelin
|
| Pecheniuk N. M., Deguchi H., Griffin J. H. |
| |
|
Activated protein C as a proteolytically activable antioxidant, anticoagulant protein
|
| Yamaji K., Abeyama K., Kawahara K., Wang Y., Liu Y., Hashiguchi T., Maruyama I. |
| |
|
Activated protein C attenuates coagulation associated over-expression of fibrinolytic activity by suppressing thrombin-dependent PAI-1 inactivation
|
|
| |
|
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium
|
| Berry L. R., Patel S., Chan A. K. C. |
| |
|
Activated protein C induces angiogenesis in vivo and in vitro
|
| Uchiba M., Okajima K., Oike Y., Ito Y., Suda T. |
| |
|
Activated protein C resistance (APCR) and combined oral contraceptives: acquired APCR is more pronounced in women receiving desogestrel containing COCs than those containing levonorgestrel and is associated with low protein S levels
|
| Gardiner C., Mackie I. J., Piegsa K., Furs S. A., Guillebaud J., Machin S. |
| |
|
Activated protein C resistance in cancer-associated venous thromboembolism
|
| Goldenberg N., Kahn S. R., Solymoss S. |
| |
|
Activated Recombinant Factor VII (rFVIIa) for the reversal of hepatic and warfarin induced coagulopathy prior to invasive procedures
|
| Chai S. J., Macik B. G. |
| |
|
Activated TAFIa down-regulates the pro-inflammatory activity of thrombin cleaved osteopontin
|
| Myles T., Leung L. L. K. |
| |
|
Activated thrombin–activatable fibrinolysis inhibitor (TAFIa) prevents spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs
|
| Wu C., Dong N., Da Cunha V., Martin-Mcnulty B., Tran K., Nagashima M., Wu Q., Morser J., Wang Y. X. |
| |
|
Activation of a novel 33-kDa SER/THR kinase by tyrosine kinase and calpain in thrombin-stimulated platelets
|
| Ido M., Hayashi T., Suzuki K. |
| |
|
Activation of anti-coagulating system by gelatin introduction to animals
|
| Lyapina L., Pastorova V. E., Uljanov A. M., Smolina T. YU. |
| |
|
Activation of blood coagulation in patients undergoing perioperative blood salvage and reinfusion of no-washed whole blood after total knee arthroplasty
|
| Filippucci E., Biagini D., Pagliaricci S., Agnelli G. |
| |
|
Activation of factor IX by erythrocyte membranes is a trigger for coagulation at stasis
|
| Kaibara M., Iwata H., Himeno R., Ujiie H. |
| |
|
Activation of factor XIII in whole plasma: the influence of Val34Leu polymorphism
|
| Muszbek L., Shemirani A. H., Haramura G. |
| |
|
Activation of human platelets by sub-nanomolar alpha-thrombin requires participation of both PAR-1 and PAR-4
|
| Ofosu F. A. |
| |
|
Activation of neutrophils by antibodies generated in heparin-induced thrombocytopenia
|
| Jeske W., Sinno S., Thoreson A., Prechel M. M., Walenga J. M. |
| |
|
Activation of p38 MAP kinase in human platelets stimulated by von Willebrand factor
|
| Canobbio I., Reineri S., Sinigaglia F., Balduini C., Torti M. |
| |
|
Activation of p38 MAPK promotes an endothelial adhesive phenotype in response to anti-phospholipid antibodies
|
| Simoncini S., Sapet C., Sanmarco M., Harlé J. R., Sampol J., Dignat-George F., Anfosso F. |
| |
|
Activation of platelets by HIT antibodies in vitro is not dependent on the presence of heparin
|
| Prechel M. M., Woznica D. V., Mcdonald M. K., Walenga J. M. |
| |
|
Activation of pp125FAK by type 2B recombinant von Willebrand factor binding to platelet GPIb at high shear rate occurs independently of aIIb3 engagement
|
| Mekrache M., Bachelot-Loza C., Ajzenberg N., Saci A., Legendre P., Baruch D. |
| |
|
Activation of RhoA and Rac through Gq- and G12/G13-mediated pathways in mouse and human platelets stimulated by TXA2 or ADP
|
| Soulet C., Gratacap M. P., Hechler B., Plantavid M., Offermanns S., Gachet C., Payrastre B. |
| |
|
Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction
|
| Merlini P., Cugno M., Ardissino D., Bottasso B., Coppola R., Mannucci P. M. |
| |
|
Activation of the platelet integrin aIIbb3 by thermodynamic modulation of transmembrane helix associations
|
| Bennett J., Li R., Vilaire G., Gratkowski H., Mitra N., Li W., Lear J. D., DeGrado W. F. |
| |
|
Active thrombin concentrations and the rate of thrombin inhibition during cardiopulmonary bypass
|
| Velan T., Chandler W. L. |
| |
|
Activity of endogenous fibrinolytic system induced by exercise ECG test in patients with previous positive ECG-exercise test but without essential atherosclerotic changes in coronaries during angiography
|
| Filipiak K. J., Rdzanek A., Karpinski G., Grabowski M., Opolski G. |
| |
|
Acute deep vein thrombosis: A prospective registry of 5451 patients
|
| Goldhaber S. Z., Tapson V. F. |
| |
|
Acute hyperglycemia enhances platelet secretion but not platelet aggregation
|
| Li N., Forslund M., Daleskog M., Johansson M. C., Hillelson P. |
| |
|
Acute ischemic strokes: LMWHs or aspirin administration and laboratory follow-up
|
| Makris P., Baltatzi M., Iliadis F., Savopoulos C., Girtovitis F., Anestakis D., Hatzitolios A. |
| |
|
Acute ischemic strokes: LMWHs or aspirin administration and laboratory monitoring
|
| Makris P., Baltatzi M., Iliadis F., Savopoulos CH., Girtovitis F., Anestakis D., Hatzitolios A. I. |
| |
|
Acute myocardial infarction in a child with patent foramen ovale and atrial septal aneurysm
|
| Ries M. D. |
| |
|
ADAMTS-13 activity and corresponding inhibitor titers during plasma exchange therapy in 13 pts with Thrombotic Thromobcytopenic Purpura (TTP)
|
| Böhm M., Betz C., Krause M., Miesbach W., Bergmann L., Scharrer I. |
| |
|
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS-13
|
| Plaimauer B., Antoine G., Grillowitzer M., Zimmermann K., Studt J. D., Lämmle B., Scheiflinger F. |
| |
|
ADAMTS13 mutations identified in familial TTP patients result in loss of VWF-cleaving protease activity
|
| Motto D., Levy G., Mcgee B., Tsai H., Ginsburg D. |
| |
|
ADAMTS13 structure and function
|
| Sadler E. |
| |
|
Additive anti-angiogenic effects of trapidil and cyproheptadine in the chick area vasculosa angiogenesis model
|
| Neubauer I., Nowak G. |
| |
|
Adhesion of normal erythrocytes at depressed venous shear rates to activated neutrophils, activated platelets, and fibrin polymerized from plasma
|
| Diamond S. L., Goel M. |
| |
|
Administration of gentamicin does not increase factor levels in severe hemophilia-B due to premature termination codons
|
| Srivastava A., Viswabandya A., Baidya S., Jayandharan G., George B., Shaji R. V., Chandy M. |
| |
|
ADP receptors and signaling pathways
|
| Gachet C. |
| |
|
ADP regulates the expressions of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1(PAI-1) in rat aortic endothelial cells
|
| Hisato K., Hajime T., Shingo Y., Naoki U., Kunieda Y., Hidehiko K., Shinzo K., Sugano T., Katsumi N., Masao N. |
| |
|
ADP-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
|
| Fontana P., Dupont A., Gandrille S., Bachelot-Loza C., Reny J., Aiach M., Gaussem P. |
| |
|
Advantage of the ‘Quick’ thrombolysis by streptokinase (SK)
|
| Gnezdilova N., Khlevchuk T., Bokarev I. |
| |
|
Advoy – a useful clinical tool in the management of the patient with hemophilia on home therapy
|
| Stephensen D., Winter M. |
| |
|
Advoy – a communication tool for better care in haemophilia
|
| Mcwhirter W., Stackelberg J. |
| |
|
Affinity-trap protease reactor for single-step conversion/purification of angiostatin from human plasma
|
| Hasumi K., Shimizu K., Narasaki R. |
| |
|
Age and first INR after standard initiation of oral anti-coagulant therapy with acenocoumarol predict the maintenance dosage
|
| Van Geest-Daalderop J. H. H., Hutten B. A., Sturk A., Levi M. M. |
| |
|
Age but not the presence of cancer predicts impairment of the protein C pathway in surgical patients
|
| Korte W., Jung K., Gabi K. |
| |
|
Age influence on D-Dimer in a large normal French population: the FITENAT study
|
| Roussi J., Mazoyer E., Gueguen R., Guillin M. C., dit Bal C., Sollier , Demoulin M. L., Bru S., Trocherie C., Drouet L., The French Haemostasis Group, GEHT |
| |
|
Aggregometric evidence of a progressive reduction of platelet sensitivity to aspirin
|
| Pulcinelli F., Pignatelli P., Celestini A., Riondino S., Violi F., Gazzaniga P. P. |
| |
|
Aggretin, a snake venom-derived endothelial integrin a 2b 1 agonist, induces angiogenesis in vitro and in vivo via expression of vascular endothelial growth factor
|
| Huang T. F., Chung C. H. |
| |
|
Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse
|
| Yamamoto K., Shimokawa T., Yi H., Isobe K., Kojima T., Loskutoff D. J., Saito H. |
| |
|
Aging of ancestral mutations causing factor VII deficiency and Dubin–Johnson syndrome in Iranian and Moroccan Jews reflects ancient Jewish migrations
|
| Mor-Cohen R., Amit Y., Kovalski V., Rosenberg N., Zivelin A., Seligsohn U. |
| |
|
Agreement between FXIII activity assays and calibrator plasma pools: the need for a FXIII reference standard with regulatory recognition
|
| Zuckerman L. A., Lewis K. B., Volpone J., Bethel M., Thayer E., Mcmillen S., Heffernan J., Rosser J., Pederson S., Ramanathan R., Gasper S., Bishop P. D. |
| |
|
Allelic frequencies of thrombophilic polymorphisms among African-Americans
|
| James A. |
| |
|
Allelic heterogeneity of severe factor V deficiency: doubling of the mutational spectrum of the factor V gene, and expression of the identified missense mutations
|
| Asselta R., Montefusco M. C., Duga S., Peyvandi F., Santagostino E., Malcovati M., Mannucci P. M., Tenchini M. L. |
| |
|
Alpha 1-anti-trypsin concentration and atheromatosis risk factors in patients with abdominal aorta aneurysmata
|
| Knapik-Kordecka M., Doskocz R. E., Adamiec R. |
| |
|
Alpha-fibrinogen Thr 312 Ala polymorphism in Turkish population
|
| Ataç F., Özbek N., Verdi H., Önerci Ö., Doðan Ö., Þahinoðlu M., þahin F. Ý. |
| |
|
Alteration of the KGD sequence in fibrinogen b-chain slowed platelet mediated clot retraction
|
| Lounes K. C., Ping L. F., Lord S. T. |
| |
|
Alterations in intraplatelet Ca2+ mobilization by functional antiheparin-PF4 antibodies: Implications in the signaling mechanisms during HIT pathogenesis
|
| Ahmad S., Choudhary S., Bacher P., Iqbal O., Sayeed M. M. |
| |
|
Alterations in lipoprotein homeostasis during experimental and clinical sepsis in primates
|
| Levels J. H. M., Pajkrt D., Schultz M., Van Den Ende A. E., Hoek F. J., Van Tol A., Taylor F. B., Hack C. E., Meijers J. C., Van Deventer S. J. |
| |
|
Alterations to the Leu444 (P1) residue of heparin cofactor II: Similarities and dissimilarities to HCII (L444R)
|
| Sutherland J. S., Bhakta V., Sheffield W. P. |
| |
|
Altered regulation of in vivo coagulation in orthopedic patients prior to knee or hip replacement surgery
|
| Ofosu F. A., Craven S., Dewar L., Ginsberg J. |
| |
|
Altered vascular remodeling in hyperfibrinogenemic mice
|
| Lord S. T., Kerlin B., Cooley B. C., Isermann B. H., Hartwig C., Zogg M., Hendrickson S. B., Mosesson M. W., Weiler H. |
| |
|
Alternate day immune tolerance regimen in severe hemophilia A with high titer inhibitors: a single center's experience
|
| Brandao L., Dimichele D. |
| |
|
Alternative second-line treatment for chronic immune thrombocytopenic purpura with sulphasalazine
|
| Ozelo M. C., Paula E. V., Fabri D. R., Annichino-Bizzacchi J. M. |
| |
|
Amino acid sequences in factor Xa that bind prothrombin and factor Va
|
| Yegneswaran S., Mesters R. M., Griffin J. H. |
| |
|
Amino acid sequences in human prothrombin that interact with factor Xa and factor Va
|
| Yegneswaran S., Mesters R. M., Griffin J. H. |
| |
|
An in vivo model to study von Willebrand factor (VWF) clearance: fundamental aspects and application to the Arg1205His Vicenza mutation
|
| Denis C. V., Schiphorst M., Ribba A. S., Westein E., De Groot P. G., Meyer D., Lenting P. J. |
| |
|
An in vitro model for assessing the thrombogenic potential of mechanical prosthetic heart valves
|
| Martin A., Christy J. R. E. |
| |
|
An alternative model for management of oral anticoagulant therapy: role of general practitioners with support of a computerized system and a portable coagulometer
|
| Manotti C., Pattacini C., Tagliaferri A., Zurlini C. |
| |
|
An analysis of the platelet transcriptome using commercial microarrays
|
| McRedmond J., Park S., Reilly D., O'Neill C., Fitzgerald D. J. |
| |
|
An ancient von Willebrand Disease (VWD) mutation that associates with a common haplotype in ~14% of type 1 VWD patients
|
| O'Brien L., James P., Othman M., Cameron C., Notley C., Hegadorn C., Sutherland J., Hough C., Rivard G. E., O'Shaunessey D., Lillicrap D. |
| |
|
An anti-idiotypic mouse monoclonal antibody towards idiotopes of human anti-C2 inhibitors mimics C2 the 3D conformation of C2 and restores Factor VIII activity in vivo
|
| Gilles J. G., Grailly S., De Maeyer M., Jacquemin M., Vander Elst L., Saint-Remy J.-M. |
| |
|
An assessment of the appropriateness of published pediatric dosage guidelines for low molecular weight heparin (Enoxaparin) in a tertiary care institution
|
| Ho S. H., Wu J. K., Hamilton D. P., Dix D. B., Wadsworth L. D. |
| |
|
An economic evaluation of the costs and benefits of heparin rationalisation in a UK hospital
|
| Cooke J., Youman P., Lloyd A., Hutchings A. |
| |
|
An evaluation of 30 years of hemophilia treatment in the Netherlands
|
| Plug I., Peters M., Mauser-Bunschoten E. P., De Goede-Bolder A., Heijnen L., Triemstra A. H. M., Willemse J., Smit C., Zwart J. E. F., Rosendaal F. R. |
| |
|
An evaluation of existing measurement methods in assessing menstrual blood loss in women with hereditary bleeding disorders
|
| Kawaja M., Scully M.-F., Barrett B., Walsh M. |
| |
|
An evaluation of four methods of external quality assurance (EQA) for patient self-management (PSM) of oral anti-coagulation: report on 97 patients
|
| Murray E., Jennings I., Kitchen S., Kitchen D., Woods T., Preston E., Mccahon D., Fuller C., Fitzmaurice D. |
| |
|
An evaluation of preoperative hemostatic variables as risk factors for deep venous thrombosis after elective lower limb arthroplasty
|
| Low J., Ma D., Courtenay B., Neil M., Mcgrath M. |
| |
|
An improved multimeric analysis identifies a subgroup of patients with Type 1 von Willebrand disease characterized by reduced VWF:RCo/Ag ratio
|
| Budde U., Castaman G., Peake I., Goodeve A., Batlle J., Meyer D., Mazurier C., Goudemand J., Eikenboom J. C. J., Schneppenheim R., Ingerslev J., Vorlova Z., Habart D., Holmberg L., Lethagen S., Pasi J., Hill F., Rodeghiero F., Federici A. B. |
| |
|
An improved simpler method for using the ReFacto™ Laboratory Standard in monitoring patients receiving BDDrFVIII
|
| Hillman-Wisman C., Llanto L., Hollon W., Lusher J. M. |
| |
|
An in silico analysis of type 2 A von Willebrand disease mutations
|
| O'Brien L., Sutherland J., Weaver D., Lillicrap D. |
| |
|
An interactive coagulation laboratory database benefiting the entire Hemophilia Center team
|
| Hillman-Wiseman C., Kulman B., Hollon W., Fusinsck K., Llanto L., Williams J., Lusher J. M. |
| |
|
An intracellular cofactor of Factor VII activating protease (FSAP) functions as an initiator of blood coagulation
|
| Nakazawa F., Kannemeier C., Trusheim H., Koyama T., Preissner K. T. |
| |
|
An overview on HIT
|
| Kelton J. |
| |
|
An unusual case of acquired giant platelet syndrome with May Hegglin features and Hermansky-Pudlak-like platelets
|
| Brummitt D., Barker H. F., Wagner B. E. |
| |
|
Analysis of 100 Iranian patients with factor XIII (sub unit A) deficiency
|
| Lak M., Sharifiyan R. A., Peyvandi F., Mannucci P. P. |
| |
|
Analysis of ADAMTS13 activity in consecutive patients with clinically diagnosed thrombotic thrombocytopenic purpura – hemolytic uremic syndrome (TTP-HUS)
|
| Vesely S., George J. N., Lammle B., Studt J.-D., Alberio L. |
| |
|
Analysis of adult patients with von Willebrand disorder in South Australia
|
| Lloyd J. V., Mangos H. M., Rodgers S. E., Duncan E. M. |
| |
|
Analysis of Arg-Gly-Asp contact sites in the av subunit of integrin avb3 employing single amino acid mutations
|
| Honda S., Tomiyama Y., Kashiwagi H., Kiyoi T., Kato H., Kosugi S., Shiraga M., Kurata Y., Matsuzawa Y. |
| |
|
Analysis of mRNA in a panel of hemophilia A patients with no detectable mutation in the coding regions of the factor VIII gene
|
| El-Maarri O., Herbiniaux U., Watzka M., Graw J., Uen C., Schröder J., Brackmann H. H., Schramm W., Schwaab R., Seifried E., Oldenburg J. |
| |
|
Analysis of storage and regulated secretion of three human variants of von Willebrand factor provides new insights into von Willebrand's disease
|
| Michaux G., Hewlett L., Messenger S., Daly M. E., Goodeve A. C., Peake I. R., Cutler D. |
| |
|
Analysis of the effectiveness of the D-Dimer test to exclude acute venous thromboembolism
|
| Rached R. A., Cavalheiro-Filho C., De Piano L. P. A., Rached R. D. V. A., Strunz C. M. C., Cardos L. F., Chamone D. A. F. |
| |
|
Analysis of the HPS-1 gene in patients with single platelet dense-granule deficiency and mild bleeding diathesis
|
| Corral J., Pujol-Moix C., González-Conejero R., Miñano A., Pérez-Ceballos E., Rivera J., Lozano M.L., Vicente V. |
| |
|
Analysis of the molecular mechanism of factor VII (FVII) deficiency caused by IVS2 + 1 donor splice sites mutation by ‘Exon Trapping System’ technique
|
| Garagiola I., Peyvandi F., Mannucci P.M. |
| |
|
Analysis of the Rho-kinase/LIM-kinase/cofilin signaling pathway in activated platelets
|
| Pandey D., Goyal P., Bamburg J. R., Siess W. |
| |
|
Analytical comparison of recombinant and plasma-derived activated protein C (APC)
|
| Weber A., Nikolic N., Varadi K., Turecek P. L., Schwarz H. P. |
| |
|
Analytical validation of the automated measurement on STA-R of the ristocetin cofactor activity (VWF:RCo) of von Willebrand factor
|
| Caron C., Trossaert M., Barat N., Nicham F., Fressinaud E., Goudemand J. |
| |
|
Anaphylactic reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT)
|
| Greinacher A., Eichler P., Lubenow N. |
| |
|
Androgen receptor-mediated suppression of tissue factor gene expression in male reproductive organs
|
| Nakamura S., Jung-Im H., Ito M. |
| |
|
Angiotensin converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation
|
| Gensini F., Padeletti L., Fatini C., Sticchi E., Colella A., Pieragnoli P., Giuello A., Musilli N., Porciani M. C., Abbate R., Gensini G. F., Michelucci A. |
| |
|
Angiotensinogen gene polymorphisms Met235Thr, G(-6)A, and A(-20)C in women with a history of pre-eclampsia or HELLP syndrome – preliminary results
|
| Moessmer G., Müller B., Artmann A. |
| |
|
Annexin A5 resistance in the antiphospholipid (aPL) syndrome
|
| Rand J., WU X.-X, Ortel T. L. |
| |
|
Anti-angiogenic activity of heparins and anti-thrombin
|
| Shalhoub J., Scully M. F., Kakkar A. K. |
| |
|
Anti-apoptotic effect of coagulation factor VIIa
|
| Sorensen B. B., Rao L. V. M., Tornehave D., Gammeltoft S., Petersen L. C. |
| |
|
Anticardiolipin antibodies and pregnancy outcome: a prospective study in an unselected obstetric population
|
| Clark P., Mcculloch N., Conkie J. A., Walker I. D., Greer I. A. |
| |
|
Anti-CD63 monoclonal antibodies inhibit platelet spreading on immobilized fibrinogen
|
| Israels S. J., McMillan-Ward E. M. |
| |
|
Anti-coagulant effects of direct thrombin inhibitors: compared for potential use in clinical practice
|
| Fenyvesi T., Harenberg J., Trager I., Giese C., Jorg I. |
| |
|
Anticoagulant effects of marinorm in coronary artery disease patients with hyperlipidemia
|
| Karayeva N. |
| |
|
Anticoagulant function of lactadherin correlates with phosphatidyl-L-serine specificity
|
| Gilbert G. E., Shi J., Heegaard C. W., Rasmussen J. T. |
| |
|
Anticoagulant heparan sulfate proteoglycans in mammalian reproductive function
|
| Dong J. C., Princivalle M., Swhorak N., de Agostini A. |
| |
|
Anticoagulant prophylaxis usage in cancer patients undergoing treatment
|
| Kirwan C., Byrne G. J., Nath E., Mccollum C. N. |
| |
|
Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis
|
| Andre P., Larocca T., Vincent D., Sinha U., Delaney S., Koller B., Conley P., Phillips D. R. |
| |
|
Anti-coagulation clinics for children achieve improved warfarin management
|
| Newall F., Savoia H. F., Campbell J., Browne M., Greenway A., Monagle P. |
| |
|
Anticoagulation therapy outcome in children after extracardiac conduit Fontan operation
|
| Hendler M., Meschengieser S. S., Conejeros Parodi W., Schlichter A. J., Kreutzer G. O., Casais P., Lazzari M. A. |
| |
|
Anti-endothelial cell antibodies (AECA): cDNA-based antigen screening
|
| Otte J., Madlener K., Jung O., Lange U., Poetzsch B. |
| |
|
Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding
|
| Ajzner E., Balogh I., Haramura G., Boda Z., Kalmar K., Pfliegler G. Y., Dahlback B., Muszbek L. |
| |
|
Anti-fibrinogen IgG from a thrombophilic A alpha R16C (Fibrinogen Northspring) proband accelerates release of clot bound thrombin by enhancing fibrinolysis: a novel thrombogenic mechanism
|
| Galanakis D., Kudryk B., Henschen A., Marchi R., Rohoza A., Ahad M. Z., Nagaswami C., Weisel J., Spitzer S. |
| |
|
Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo
|
| Abid Hussein M., Meesters E. W., Osmanovic N., Romijn F. P. H., Th M., Nieuwland R., Sturk A. |
| |
|
Anti-hemostasis stimulated by the medicinal leech application as a result of mast cells activation by the leech saliva
|
| Baskova I. P., Goltsova K. V., Umarova B. A., Zavalova L. L. |
| |
|
Anti-hypertensive treatment restores impaired local fibrinolysis in essential hypertension
|
| Hrafnkelsdottir T., Ridderstråle W., Jern S. |
| |
|
Anti-inflammatory mechanisms of PS3, a new drug candidate with both anti-inflammatory and anti-thrombotic activities
|
| Alban S., Becker M., Franz G. |
| |
|
Anti-metastatic effect of an anti-human tissue factor monoclonal antibody on human breast and prostate experimental metastasis models in nude mice
|
| Wen J. H., Wong H. C., Jiao J. A. |
| |
|
Antioxidant effect of wine in human: role of polyphenols
|
| Pignatelli P., Lenti L., Pulcinelli F. M., Natella F., Musella L., Germanò G., Gazzaniga P. P., Ghiselli A., Violi F. |
| |
|
Anti-oxidized LDL antibodies in patients with abdominal aorta aneurysm and arteriosclerosis obliterans
|
| Doskocz R. E., Knapik-Kordeck M., Adamiec R. |
| |
|
Anti-phospholipid antibodies and carotid-artery intima-media thickness in young survivors of myocardial infarction
|
| Dropinski J., Szczeklik W., Rubis P., Sydor W. J. |
| |
|
Anti-phospholipid antibodies and hyperhomocysteinemia: response to therapy with folic acid
|
| Casais P., Alberto M. F., Gennari L. C., Meschengieser S. S., Sanchez Luceros A., Blanco A. N., Lazzari M. A. |
| |
|
Anti-phospholipid antibodies in ischemic stroke
|
| Gilmore G., Thom J. Y., Yi Q., Eikelboom J. W., Baker R. I., Hankey G. J. |
| |
|
Antiphospholipid antibodies in patients diagnosed for thrombophilia
|
| Janczak J., Lewandowski K., Kolacz E., Turowiecka Z., Zozulinska M., Kazmierczak M., Zawilska K. |
| |
|
Anti-phospholipid syndrome during pregnancy: only the high-dose of LMWH thromboprophylaxis is successful
|
| Boda Z., Laszlo P., Schlammadinger A., Razso K., Pfliegler G., Posan E. |
| |
|
Anti-phospholipid syndrome in systemic lupus erythematosus
|
| Zacharof A., Zacharof H., Zacharof L. |
| |
|
Antiphospholipid syndrome: clinical diversity and anti-thrombotic therapy
|
| Greaves M. |
| |
|
Antiphospholipid/antiprotein antibodies and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case–control study
|
| Gris J. C., Perneger T. V., Quéré I., Mercier E., Hoffet M., Déchaud H., Daurès J. P., Marès P., Dauzat M. |
| |
|
Antiplatelet agents and statins in secondary prevention: which patients and which agents
|
| Collins R. |
| |
|
Anti-platelet agents clopidogrel and aspirin inhibit expression of tissue factor procoagulant activity in patients with peripheral artery disease
|
| Vaidyula V. R., Abdel-Hafiz E., Bagga S., Jalagadugula G., Wilhite D., Comerota A. J., Rao A. K. |
| |
|
Anti-platelet and anti-thrombotic effects of CS-747, a novel P2Y12 receptor antagonist, in combination with aspirin
|
| Sugidachi A., Ogawa T., Isobe T., Shimoji T., Suzuki N., Kakusaka M., Asai F. |
| |
|
Anti-protein S antibodies in patients with venous and/or arterial thrombosis
|
| Montaruli B., Agnes C., Foli C., Vaccarino A., Rus C., Saitta M., Bazzan M. |
| |
|
Anti-protein Z antibodies in women with abnormal pregnancies
|
| Gris J. C., Amadio C., Mercier E., Lavigne G., Déchaud H., Hoffet M., Quéré I., Amiral J., Dauzat M., Marès P. |
| |
|
Anti-prothrombin antibodies in patients with recurrent venous thromboembolism
|
| Zanon E., Saggiorato G., Ramon R., Carraro G., Girolami A. |
| |
|
Anti-thrombin F229L: a new homozygous variant leading to spontaneous anti-thrombin polymerization in vivo and severe childhood thrombosis
|
| Picard V., Dautzenberg M-D., Villoutreix B. O., Orliaguet G., Alhenc-Gelas M., Aiach M. |
| |
|
Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft
|
| Cozzi E., Ancona E., Boldrin M., Fadin M., Gavasso S., Zerbinati P., Tognin G., Katopodis A., Bedendo S., Fante F., Lideo L., Baldan N., Busetto R., Girolami A., Simioni P. |
| |
|
Anti-thrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and conformational activation
|
| Jairajpuri M. A., Lu A., Desai U., Olson S. T., Bjork I., Bock S. C. |
| |
|
Antithrombin suppresses endotoxin-induced hypotension through the effect of calcitonin gene-related peptide
|
| Isobe H., Okajima K., Uchiba M., Harada N. |
| |
|
Antithrombin-mediated inhibition of factor IXa by synthetic oligosaccharides
|
| Herault J.-P., Gaich C., Bono F., Driguez P.-A., Duchaussoy P., Petitou M., Herbert J.-M |
| |
|
Antithrombotic action of perindopril in experimental venous thrombosis in young rats
|
| Buczko W., Stankiewicz L., Buczko P., Chabielska E. |
| |
|
Anti-thrombotic and anticoagulant effects of S35898 an orally active thrombin inhibitor
|
| Rupin A., Vallez M. O., Versluys D., Gloanec P., De Nanteuil G., Verbeuren T. J. |
| |
|
Anti-thrombotic effect of combination of low molecular weight heparin with low doses of unfractionated heparin in experimental venous thrombosis
|
| Carelli G., Maffei F. H. A., Mattar L., Ferrari I. C., Carvalho L. C. |
| |
|
Anti-thrombotic effect of YM337 on carotid artery thrombi induced in squirrel monkeys by electrical stimulation
|
| Kaku S., Uemura T., Saitoh M., Miyata K. |
| |
|
Anti-thrombotic effects of ER112787, a novel, nonpeptide thrombin receptor (PAR-1) antagonist, in a photochemically induced thrombosis model using guinea pigs
|
| Matsuoka T., Kogushi M., Kobayashi H., Ono N., Kawata T., Kawahara T., Suzuki S., Hishinuma I. |
| |
|
Antithrombotic effects of selective P2Y1 and P2Y12 antagonists in anesthetized rats
|
| Vemulapalli S., Kurowski S., Fantuzzi J., Sabin C., Clasby M., Chackalamannil S., Hunter J., Graziano M., Chintala M. |
| |
|
Anti-thrombotic effects of tumor necrosis factor-a
|
| Cambien B., Bergmeier W., Saffaripour S., Wagner D. |
| |
|
Anti-thrombotic treatment after coronary artery bypass graft surgery (CABGS):economic consequence of a change in regimen
|
| Carre E., Joseph P., Ffrench P., Jegaden O., Wozniczko D., Rochefort F., Lehot J. J. |
| |
|
APC resistance, new perspectives
|
| Rosing J. |
| |
|
Apoptotic effect of cleaved high molecular weight kininogen is selectively regulated by extracellular matrix proteins
|
| Guo Y.-L., Wang S. J., Cao D. J., Colman R. W. |
| |
|
Application of a novel polypeptide affinity ligand for purification of recombinant FVIII
|
| Kelley B. D., Booth J., Tannatt M., Magnusson R., Hagelberg S. |
| |
|
Application of human factor XIII in children with massive pleural effusions after open heart surgery
|
| Schroth M., Singer H., Scharf J., Cesnjevar R., Klinge J. |
| |
|
APTT Clot Waveform Analysis in Patients Presenting with Sepsis to the Emergency Department
|
| Hayes T. |
| |
|
APTT transmittance waveform analysis in a cohort of septic patients
|
| Lang B. J., Hayes T. E., Burton J. H., Riker R. R. |
| |
|
Are daily doses of 80 and 160 mg of aspirin bioequivalent? A pharmacokinetic and pharmacodynamic approach
|
| Cerletti C., Dell'elba G., Manarini S., Pecce R., Di Castelnuovo A., Scorpiglione N., Feliziani V., De Gaetano G. |
| |
|
Are there really undetectable Factor VIII mutations in hemophilia A? How can we deal with the difficult ones?
|
| Theophilus B., Williams I. J., Enayat M. S., Williams M. D., Wilde J. T., Hill F. G. H. |
| |
|
Argatroban anticoagulation inhibits thrombin generation and its rebound during percutaneous interventional procedures
|
| Fareed J., Lewis B., Iqbal O., Walenga J., Wrona L., Messmore H., Leya F. |
| |
|
Argatroban in HIT type II: clinical experience - trials and practice
|
| Lewis B. |
| |
|
Arterial ischemic stroke (AIS) in children: a prospective 10-year registry in Argentina
|
| Bonduel M., Sciuccati G., Hepner M., Pieroni G., Feliu Torres A., Frontroth J., Serviddio M. R. |
| |
|
Arterial thromboembolic complications in chi |
